Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James H Maccabe

Showing results (101-110 of 137) with videos related to

Pageof 14
Sort By:
Brain, Behavior, and Immunity|May 14, 2023
The association between peripheral inflammation, brain glutamate and antipsychotic response in Schizophrenia: Data from the STRATA collaborationSunniva Fenn-Moltu, Bill Deakin, Richard Drake, et al.
Plos One|December 8, 2020
The side effect profile of Clozapine in real world data of three large mental health hospitalsEhtesham Iqbal, Risha Govind, Alvin Romero, et al.
Schizophrenia Research|May 22, 2021
Gender disparities in clozapine prescription in a cohort of treatment-resistant schizophrenia in the South London and Maudsley case registerEmma Wellesley Wesley, India Patel, Giouliana Kadra-Scalzo, et al.
Biological Psychiatry|June 25, 2025
Why Is Clozapine Uniquely Effective in Treatment-Resistant Schizophrenia? A Review and ProposalRobin M Murray, Alice Egerton, Yueming Gao, et al.
Social Psychiatry and Psychiatric Epidemiology|March 5, 2022
Ethnic inequalities in clozapine use among people with treatment-resistant schizophrenia: a retrospective cohort study using data from electronic clinical recordsDaniela Fonseca de Freitas, India Patel, Giouliana Kadra-Scalzo, et al.
Pharmacogenomics|November 19, 2013
Opening Pandora's box in the UK: a hypothetical pharmacogenetic test for clozapineBenjamin W J Spencer, Barbara Prainsack, Dan Rujescu, et al.
Journal of Psychopharmacology (Oxford, England)|January 8, 2026
Associations between glutamate and cerebral blood flow in treatment-resistant schizophrenia during clozapine treatmentJunyu Sun, Fernando Zelaya, Kyra-Verena Sendt, et al.
The Journal of Clinical Psychiatry|September 28, 2022
Prevalence and Correlates of Obsessive-Compulsive Symptoms in Individuals With Schizophrenia, Schizoaffective Disorder, or Bipolar DisorderDeborah Ahn-Robbins, Nina H Grootendorst-van Mil, Chin-Kuo Chang, et al.
Schizophrenia Bulletin|January 26, 2018
Negative Symptoms in Early-Onset Psychosis and Their Association With Antipsychotic Treatment FailureJohnny Downs, Harry Dean, Suzannah Lechler, et al.
Molecular Psychiatry|January 17, 2019
A genome-wide association study in individuals of African ancestry reveals the importance of the Duffy-null genotype in the assessment of clozapine-related neutropeniaSophie E Legge, Antonio F Pardiñas, Marinka Helthuis, et al.
Pageof 14

Showing results (101-110 of 137) with videos related to

Sort By:
Pageof 14
Brain, Behavior, and Immunity|May 14, 2023
The association between peripheral inflammation, brain glutamate and antipsychotic response in Schizophrenia: Data from the STRATA collaborationSunniva Fenn-Moltu, Bill Deakin, Richard Drake, et al.
Plos One|December 8, 2020
The side effect profile of Clozapine in real world data of three large mental health hospitalsEhtesham Iqbal, Risha Govind, Alvin Romero, et al.
Schizophrenia Research|May 22, 2021
Gender disparities in clozapine prescription in a cohort of treatment-resistant schizophrenia in the South London and Maudsley case registerEmma Wellesley Wesley, India Patel, Giouliana Kadra-Scalzo, et al.
Biological Psychiatry|June 25, 2025
Why Is Clozapine Uniquely Effective in Treatment-Resistant Schizophrenia? A Review and ProposalRobin M Murray, Alice Egerton, Yueming Gao, et al.
Social Psychiatry and Psychiatric Epidemiology|March 5, 2022
Ethnic inequalities in clozapine use among people with treatment-resistant schizophrenia: a retrospective cohort study using data from electronic clinical recordsDaniela Fonseca de Freitas, India Patel, Giouliana Kadra-Scalzo, et al.
Pharmacogenomics|November 19, 2013
Opening Pandora's box in the UK: a hypothetical pharmacogenetic test for clozapineBenjamin W J Spencer, Barbara Prainsack, Dan Rujescu, et al.
Journal of Psychopharmacology (Oxford, England)|January 8, 2026
Associations between glutamate and cerebral blood flow in treatment-resistant schizophrenia during clozapine treatmentJunyu Sun, Fernando Zelaya, Kyra-Verena Sendt, et al.
The Journal of Clinical Psychiatry|September 28, 2022
Prevalence and Correlates of Obsessive-Compulsive Symptoms in Individuals With Schizophrenia, Schizoaffective Disorder, or Bipolar DisorderDeborah Ahn-Robbins, Nina H Grootendorst-van Mil, Chin-Kuo Chang, et al.
Schizophrenia Bulletin|January 26, 2018
Negative Symptoms in Early-Onset Psychosis and Their Association With Antipsychotic Treatment FailureJohnny Downs, Harry Dean, Suzannah Lechler, et al.
Molecular Psychiatry|January 17, 2019
A genome-wide association study in individuals of African ancestry reveals the importance of the Duffy-null genotype in the assessment of clozapine-related neutropeniaSophie E Legge, Antonio F Pardiñas, Marinka Helthuis, et al.
Pageof 14